Drug Profile

TGTX 103

Alternative Names: TGTX-103; TSHA-103

Latest Information Update: 28 May 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Texas Southwestern Medical Center
Developer Taysha Gene Therapies; University of Texas Southwestern Medical Center
Class Antiepileptic drugs; Gene therapies
Mechanism of Action Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Epilepsy
New Molecular Entity No

Highest Development Phases

No development reported Epilepsy

Most Recent Events

28 May 2024 No recent reports of development identified for preclinical development in Epilepsy in USA (Intrathecal)
31 Dec 2023 Taysha Gene Therapies has two pending patent PCT applications for TGTX 103 in-licensed from The Board of Regents of The University of Texas System
03 Dec 2020 TGTX 103 receives Orphan Drug status for Epilepsy in USA

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com